ULVR:LSEUnilever PLC Analysis
Data as of 2026-03-09 - not real-time
£4,903.50
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Unilever’s price is currently perched near a key support level while technical signals show mixed messages – the 14‑day RSI is in oversold territory and the MACD histogram remains strongly negative, yet the broader trend is still classified as bullish.
The market price sits well above the discounted cash‑flow estimate, indicating a material overvaluation, and the forward P/E points to only modest upside. Dividend yield remains attractive for income‑focused investors, but the payout ratio is high, making sustainability a key watch‑point. Analyst consensus is neutral with a “hold” rating, and Deutsche Bank’s recent downgrade underscores valuation concerns despite the recent positive earnings momentum that has propelled the stock higher this year.
The market price sits well above the discounted cash‑flow estimate, indicating a material overvaluation, and the forward P/E points to only modest upside. Dividend yield remains attractive for income‑focused investors, but the payout ratio is high, making sustainability a key watch‑point. Analyst consensus is neutral with a “hold” rating, and Deutsche Bank’s recent downgrade underscores valuation concerns despite the recent positive earnings momentum that has propelled the stock higher this year.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near technical support
- oversold RSI suggesting potential bounce
- valuation gap between market price and DCF
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- persistent overvaluation relative to fundamentals
- steady dividend yield supporting total return
- moderate volatility and near‑zero beta limiting market‑wide risk
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- defensive consumer‑staples positioning
- strong brand portfolio and cash‑flow generation
- valuation risk remains the primary headwind
Key Metrics & Analysis
Financial Health
Profit Margin18.75%
P/E Ratio21.8
ROE30.95%
ROA8.49%
Debt/Equity160.79
P/B Ratio794.6
Op. Cash Flow£8.4B
Free Cash Flow£6.4B
Technical Analysis
TrendBullish
RSI34.2
Support£4,843.00
Resistance£5,526.00
MA 20£5,292.28
MA 50£5,037.41
MA 200£4,904.46
MACDBearish
VolumeDecreasing
Fear & Greed Index100
Valuation
Fair Value£2,977.94
Target Price£5,363.66
Upside/Downside9.38%
GradeOvervalued
TypeValue
Dividend Yield3.50%
Risk Assessment
Beta-0.01
Volatility23.78%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.